{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:52:07Z","timestamp":1791445927777,"version":"4.3.3"},"reference-count":137,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01NS134885"],"award-info":[{"award-number":["R01NS134885"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R21CA267135"],"award-info":[{"award-number":["R21CA267135"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM), the most common and lethal primary brain cancer, has a median survival of 15 months. Despite repeated efforts over 20 years to introduce life-extending therapies, little has changed in the standard of care. Recent studies have revealed that GBM cells express daily rhythms in gene expression and sensitivity to chemotherapy. In this review, we highlight the role of circadian biology in GBM growth, and its potential applications to GBM diagnosis and treatment. The hallmarks of cancer often show daily variation. We emphasize opportunities to advance our understanding of glioblastoma pathophysiology by considering how brain tumors integrate into the host circadian system and respond to daily rhythms in neuronal, paracrine, or hormonal signals to promote growth. Circadian treatment strategies include disrupting daily rhythms in GBM cells, blocking their synchronization to the host, or finding best times of day for biopsy, surgery, radiation, or chemotherapy. We discuss an ongoing temozolomide chronotherapy trial in the context of recent evidence against chronotherapy and suggest ways to critically assess time-of-day effects in GBM. With over 500 active clinical trials for GBM, it is time to evaluate, and control for, circadian rhythms in care for brain cancer patients.<\/jats:p>","DOI":"10.1093\/neuonc\/noag179","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:15:35Z","timestamp":1786101335000},"source":"Crossref","is-referenced-by-count":0,"title":["Circadian biology in brain cancer diagnosis and treatment"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2251-9583","authenticated-orcid":false,"given":"Sofia V","family":"Salvatore","sequence":"first","affiliation":[{"name":"Department of Biology, Division of Biology and Biomedical Sciences, Washington University in St. Louis , St. Louis, Missouri,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7475-5284","authenticated-orcid":false,"given":"Annika M","family":"Kaval","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine , Palo Alto, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9749-3814","authenticated-orcid":false,"given":"Erin M","family":"Gibson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine , Palo Alto, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7209-5174","authenticated-orcid":false,"given":"Erik D","family":"Herzog","sequence":"additional","affiliation":[{"name":"Department of Biology, Division of Biology and Biomedical Sciences, Washington University in St. Louis , St. Louis, Missouri,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100803020316200_noag179-B1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(25)00705-3","article-title":"20 Years of the stupp protocol: confronting stagnation in glioblastoma therapy","volume":"27","author":"Khasraw","year":"2026","journal-title":"Lancet Oncol"},{"key":"2026100803020316200_noag179-B2","doi-asserted-by":"publisher","first-page":"V1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol."},{"key":"2026100803020316200_noag179-B3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","article-title":"Glioma","volume":"10","author":"Weller","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026100803020316200_noag179-B4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41586-022-04719-9","article-title":"Olfactory sensory experience regulates gliomagenesis via neuronal IGF1","volume":"606","author":"Chen","year":"2022","journal-title":"Nature"},{"key":"2026100803020316200_noag179-B5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","article-title":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","volume":"573","author":"Venkataramani","year":"2019","journal-title":"Nature"},{"key":"2026100803020316200_noag179-B6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.cell.2015.04.012","article-title":"Neuronal activity promotes glioma growth through neuroligin-3 secretion","volume":"161","author":"Venkatesh","year":"2015","journal-title":"Cell"},{"key":"2026100803020316200_noag179-B7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41586-019-1563-y","article-title":"Electrical and synaptic integration of glioma into neural circuits","volume":"573","author":"Venkatesh","year":"2019","journal-title":"Nature"},{"key":"2026100803020316200_noag179-B8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03580-6","article-title":"NF1 mutation drives neuronal activity-dependent initiation of optic glioma","volume":"594","author":"Pan","year":"2021","journal-title":"Nature"},{"key":"2026100803020316200_noag179-B9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41586-023-06678-1","article-title":"Glioma synapses recruit mechanisms of adaptive plasticity","volume":"623","author":"Taylor","year":"2023","journal-title":"Nature"},{"key":"2026100803020316200_noag179-B10","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41586-024-08579-3","article-title":"GABAergic neuron-to-glioma synapses in diffuse midline gliomas","volume":"639","author":"Barron","year":"2025","journal-title":"Nature"},{"key":"2026100803020316200_noag179-B11","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1016\/j.cell.2025.05.031","article-title":"Cholinergic neuronal activity promotes diffuse midline glioma growth through muscarinic signaling","volume":"188","author":"Drexler","year":"2025","journal-title":"Cell"},{"key":"2026100803020316200_noag179-B12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41586-022-05520-4","article-title":"Autonomous rhythmic activity in glioma networks drives brain tumour growth","volume":"613","author":"Hausmann","year":"2023","journal-title":"Nature"},{"key":"2026100803020316200_noag179-B13","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.cell.2022.06.054","article-title":"Glioblastoma hijacks neuronal mechanisms for brain invasion","volume":"185","author":"Venkataramani","year":"2022","journal-title":"Cell"},{"key":"2026100803020316200_noag179-B14","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41467-021-21117-3","article-title":"Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma","volume":"12","author":"Jung","year":"2021","journal-title":"Nat Commun"},{"key":"2026100803020316200_noag179-B15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature16071","article-title":"Brain tumour cells interconnect to a functional and resistant network","volume":"528","author":"Osswald","year":"2015","journal-title":"Nature"},{"key":"2026100803020316200_noag179-B16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.15586\/codon.glioblastoma.2017.ch8","article-title":"Epidemiology and outcome of glioblastoma","author":"Tamimi","year":"2017","journal-title":"Glioblastoma"},{"key":"2026100803020316200_noag179-B17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/nejmoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026100803020316200_noag179-B18","doi-asserted-by":"publisher","first-page":"vdab028","DOI":"10.1093\/noajnl\/vdab028","article-title":"Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 newly diagnosed disease","volume-title":"Neurooncol Adv","author":"Taslimi","year":"2021"},{"key":"2026100803020316200_noag179-B19","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"2026100803020316200_noag179-B20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","article-title":"Glioblastoma stem cells: driving resiliency through chaos","volume":"6","author":"Prager","year":"2020","journal-title":"Trends Cancer"},{"key":"2026100803020316200_noag179-B21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcdb.2015.08.005","article-title":"Oncogenes strike a balance between cellular growth and homeostasis","volume":"43","author":"Qiu","year":"2015","journal-title":"Semin Cell Dev Biol"},{"key":"2026100803020316200_noag179-B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI198780","article-title":"Rhythms of risk: the intersection of clocks, cancer, and chronotherapy","volume":"136","author":"Mello","year":"2026","journal-title":"J Clin Invest"},{"key":"2026100803020316200_noag179-B23","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s43018-025-00981-8","article-title":"The diverse roles of the circadian clock in cancer","volume":"6","author":"Fortin","year":"2025","journal-title":"Nat Cancer"},{"key":"2026100803020316200_noag179-B24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-neuro-100322-112249","article-title":"Circadian rhythms and astrocytes: the good, the bad, and the ugly","volume":"46","author":"Hastings","year":"2023","journal-title":"Annu Rev Neurosci"},{"key":"2026100803020316200_noag179-B25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41698-024-00530-z","article-title":"Molecular mechanisms of tumour development in glioblastoma: an emerging role for the circadian clock","volume":"8","author":"Nelson","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026100803020316200_noag179-B26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics18020235","article-title":"The potential of chronotherapy and nanotherapy-based strategies for glioblastoma treatment","volume":"18","author":"Neves","year":"2026","journal-title":"Pharmaceutics"},{"key":"2026100803020316200_noag179-B27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semcdb.2021.07.017","article-title":"Circadian clock synchrony and chronotherapy opportunities in cancer treatment","volume":"126","author":"Damato","year":"2022","journal-title":"Semin Cell Dev Biol"},{"key":"2026100803020316200_noag179-B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb0738","article-title":"Clocks, cancer, and chronochemotherapy","volume":"371","author":"Sancar","year":"2021","journal-title":"Science (1979)"},{"key":"2026100803020316200_noag179-B29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ccell.2024.11.012","article-title":"Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host","volume":"43","author":"Gonzalez-Aponte","year":"2025","journal-title":"Cancer Cell"},{"key":"2026100803020316200_noag179-B30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0748730417696788","article-title":"Cell-intrinsic, Bmal1-dependent circadian regulation of temozolomide sensitivity in glioblastoma","volume":"32","author":"Slat","year":"2017","journal-title":"J Biol Rhythms"},{"key":"2026100803020316200_noag179-B31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41698-025-01205-z","article-title":"Personalized chronotherapy in glioblastoma: integrating circadian profiling and PK\u2013PD modelling to optimize temozolomide timing","volume":"10","author":"Nelson","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026100803020316200_noag179-B32","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1158\/2159-8290.CD-19-0215","article-title":"Targeting glioblastoma stem cells through disruption of the circadian clock","volume":"9","author":"Dong","year":"2019","journal-title":"Cancer Discov"},{"key":"2026100803020316200_noag179-B33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11060-023-04535-9","article-title":"Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma","volume":"166","author":"Gonzalez-Aponte","year":"2024","journal-title":"J Neurooncol"},{"key":"2026100803020316200_noag179-B34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/nop\/npac003","article-title":"A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma","volume":"9","author":"Damato","year":"2022","journal-title":"Neurooncol Pract"},{"key":"2026100803020316200_noag179-B35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature25170","article-title":"Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence","volume":"553","author":"Sulli","year":"2018","journal-title":"Nature"},{"key":"2026100803020316200_noag179-B36","doi-asserted-by":"publisher","first-page":"e2203936119","DOI":"10.1073\/pnas.2203936119","article-title":"CRY2 isoform selectivity of a circadian clock modulator with antiglioblastoma efficacy","volume":"119","author":"Miller","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026100803020316200_noag179-B37","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/neuonc\/noaf089","article-title":"Advancing clinical response against glioblastoma: evaluating SHP1705 CRY2 activator efficacy in preclinical models and safety in phase I trials","volume":"27","author":"Chan","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026100803020316200_noag179-B38","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1007\/s12035-023-03895-7","article-title":"Circadian clock gene bmal1 acts as a tumor suppressor gene in a mice model of human glioblastoma","volume":"61","author":"Trebucq","year":"2024","journal-title":"Mol Neurobiol"},{"key":"2026100803020316200_noag179-B39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.autneu.2019.02.001","article-title":"The suprachiasmatic nucleus; a responsive clock regulating homeostasis by daily changing the setpoints of physiological parameters","volume":"218","author":"Buijs","year":"2019","journal-title":"Auton Neurosci"},{"key":"2026100803020316200_noag179-B40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-642-25950-0_1","article-title":"Molecular components of the mammalian circadian clock","volume":"217","author":"Buhr","year":"2013","journal-title":"Handb Exp Pharmacol"},{"key":"2026100803020316200_noag179-B41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/35003589","article-title":"Light acts directly on organs and cells in culture to set the vertebrate circadian clock","volume":"404","author":"Whitmore","year":"2000","journal-title":"Nature"},{"key":"2026100803020316200_noag179-B42","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1126\/science.288.5466.682","article-title":"Resetting central and peripheral circadian oscillators in transgenic rats","volume":"288","author":"Yamazaki","year":"2000","journal-title":"Science (1979)"},{"key":"2026100803020316200_noag179-B43","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.1086179","article-title":"Melanopsin is required for non-image-forming photic responses in blind mice","volume":"301","author":"Panda","year":"2003","journal-title":"Science (1979)"},{"key":"2026100803020316200_noag179-B44","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1523\/jneurosci.15-08-05681.1995","article-title":"Temperature compensation and temperature entrainment of the chick pineal cell circadian clock","volume":"15","author":"Barrett","year":"1995","journal-title":"J Neurosci"},{"key":"2026100803020316200_noag179-B45","doi-asserted-by":"publisher","first-page":"21453","DOI":"10.1073\/pnas.0909591106","article-title":"Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression","volume":"106","author":"Vollmers","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026100803020316200_noag179-B46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jne.12125","article-title":"Circadian pacemaking in cells and circuits of the suprachiasmatic nucleus","volume":"26","author":"Hastings","year":"2014","journal-title":"J Neuroendocrinol"},{"key":"2026100803020316200_noag179-B47","doi-asserted-by":"publisher","first-page":"14306","DOI":"10.1073\/pnas.1101767108","article-title":"A diversity of paracrine signals sustains molecular circadian cycling in suprachiasmatic nucleus circuits","volume":"108","author":"Maywood","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026100803020316200_noag179-B48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/07487304231225706","article-title":"The suprachiasmatic nucleus at 50: looking back, then looking forward","volume":"39","author":"Ono","year":"2024","journal-title":"J Biol Rhythms"},{"key":"2026100803020316200_noag179-B49","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1038\/s41467-021-25793-z","article-title":"Identification of the suprachiasmatic nucleus venous portal system in the mammalian brain","volume":"12","author":"Yao","year":"2021","journal-title":"Nat Commun"},{"key":"2026100803020316200_noag179-B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao0318","article-title":"Diurnal transcriptome atlas of a primate across major neural and peripheral tissues","volume":"359","author":"Mure","year":"2018","journal-title":"Science (1979)"},{"key":"2026100803020316200_noag179-B51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/jn.00338.2024","article-title":"Causal associations between sleep traits, sleep disorders, and glioblastoma: a two-sample bidirectional Mendelian randomization study","volume":"133","author":"Chen","year":"2025","journal-title":"J Neurophysiol"},{"key":"2026100803020316200_noag179-B52","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S1470-2045(19)30455-3","article-title":"Carcinogenicity of night shift work","volume":"20","author":"Ward","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026100803020316200_noag179-B53","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/1570159x18666200626204005","article-title":"Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications","volume":"19","author":"Ortiz","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"2026100803020316200_noag179-B54","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","article-title":"MGMT status as a clinical biomarker in glioblastoma","volume":"6","author":"Butler","year":"2020","journal-title":"Trends Cancer"},{"key":"2026100803020316200_noag179-B55","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/neuonc\/noae108","article-title":"No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: reanalysis of the CE.6 and the pooled Nordic\/NOA-08 trials in elderly glioblastoma patients","volume":"26","author":"Hegi","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026100803020316200_noag179-B56","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/nejmoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"2026100803020316200_noag179-B57","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nop020","article-title":"MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma","volume":"12","author":"Rivera","year":"2010","journal-title":"Neuro Oncol"},{"key":"2026100803020316200_noag179-B58","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11060-025-05242-3","article-title":"Circadian variation in MGMT promoter methylation and expression predicts sensitivity to temozolomide in glioblastoma","volume":"176","author":"Gonzalez-Aponte","year":"2025","journal-title":"J Neurooncol"},{"key":"2026100803020316200_noag179-B59","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2025.11.002","article-title":"Advancing CNS tumor diagnostics with expanded DNA methylation-based classification","volume":"44","author":"Sill","year":"2026","journal-title":"Cancer Cell"},{"key":"2026100803020316200_noag179-B60","doi-asserted-by":"publisher","DOI":"10.1093\/NEUPED\/WUAF001.280","article-title":"PATH-01. The NCI\/Bethesda DNA methylation classifier: an important diagnostic tool for CNS tumors","volume":"1","author":"Singh","year":"2025","journal-title":"Neuro-Oncol Pediatrics"},{"key":"2026100803020316200_noag179-B61","doi-asserted-by":"publisher","first-page":"vdae228","DOI":"10.1093\/noajnl\/vdae228","article-title":"cIMPACT-NOW update 9: recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics","volume":"7","author":"Aldape","year":"2025","journal-title":"Neurooncol Adv"},{"key":"2026100803020316200_noag179-B62","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41588-025-02168-4","article-title":"Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics","volume":"57","author":"Spitzer","year":"2025","journal-title":"Nat Genet"},{"key":"2026100803020316200_noag179-B63","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41588-025-02167-5","article-title":"The multilayered transcriptional architecture of glioblastoma ecosystems","volume":"57","author":"Nomura","year":"2025","journal-title":"Nat Genet"},{"key":"2026100803020316200_noag179-B64","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.AAV3617","article-title":"Sleep-wake cycles drive daily dynamics of synaptic phosphorylation","volume":"366","author":"Br\u00fcning","year":"2019","journal-title":"Science (1979)"},{"key":"2026100803020316200_noag179-B65","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.AAV2642","article-title":"The forebrain synaptic transcriptome is organized by clocks but its proteome is driven by sleep","volume":"366","author":"Noya","year":"2019","journal-title":"Science (1979)"},{"key":"2026100803020316200_noag179-B66","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/neuonc\/noq030","article-title":"Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004","volume":"12","author":"Bauchet","year":"2010","journal-title":"Neuro Oncol"},{"key":"2026100803020316200_noag179-B67","doi-asserted-by":"publisher","first-page":"e194582","DOI":"10.1172\/jci.insight.194582","article-title":"Daily locomotor activity declines with tumor growth and disease progression in glioblastoma","volume":"11","author":"Gonzalez-Aponte","year":"2026","journal-title":"JCI Insight"},{"key":"2026100803020316200_noag179-B68","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.nec.2020.08.002","article-title":"Role of resection in glioblastoma management","volume":"32","author":"Youngblood","year":"2021","journal-title":"Neurosurg Clin N Am"},{"key":"2026100803020316200_noag179-B69","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jocn.2018.05.002","article-title":"Ten-year survival in glioblastoma. A systematic review","volume":"54","author":"Tykocki","year":"2018","journal-title":"J Clin Neurosci"},{"key":"2026100803020316200_noag179-B70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF02228884","article-title":"Survival and prognosis of patients with astrocytoma with atypical or anaplastic features","volume":"3","author":"Nelson","year":"1985","journal-title":"J Neurooncol"},{"key":"2026100803020316200_noag179-B71","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1081\/CBI-120002592","article-title":"Chronobiology of the mammalian response to ionizing radiation. Potential applications in oncology","volume":"19","author":"Haus","year":"2002","journal-title":"Chronobiol Int"},{"key":"2026100803020316200_noag179-B72","doi-asserted-by":"publisher","first-page":"18790","DOI":"10.1073\/pnas.1115249108","article-title":"Control of skin cancer by the circadian rhythm","volume":"108","author":"Gaddameedhi","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026100803020316200_noag179-B73","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1126\/science.1086271","article-title":"Control mechanism of the circadian clock for timing of cell division in vivo","volume":"302","author":"Matsuo","year":"2003","journal-title":"Science (1979)"},{"key":"2026100803020316200_noag179-B74","doi-asserted-by":"publisher","first-page":"E2106","DOI":"10.1073\/pnas.1215935110","article-title":"Local circadian clock gates cell cycle progression of transient amplifying cells during regenerative hair cycling","volume":"110","author":"Plikus","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026100803020316200_noag179-B75","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/15384047.2022.2041953","article-title":"Clock in radiation oncology clinics: cost-free modality to alleviate treatment-related toxicity","volume":"23","author":"Ali","year":"2022","journal-title":"Cancer Biol Ther"},{"key":"2026100803020316200_noag179-B76","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1080\/07420528.2021.1880426","article-title":"Clinical effects of morning and afternoon radiotherapy on high-grade gliomas","volume":"38","author":"Sapienza","year":"2021","journal-title":"Chronobiol Int"},{"key":"2026100803020316200_noag179-B77","doi-asserted-by":"publisher","first-page":"101068","DOI":"10.1016\/j.jbc.2021.101068","article-title":"Circadian clock, carcinogenesis, chronochemotherapy connections","volume":"297","author":"Yang","year":"2021","journal-title":"J Biol Chem"},{"key":"2026100803020316200_noag179-B78","doi-asserted-by":"publisher","first-page":"687672","DOI":"10.3389\/fonc.2021.687672","article-title":"The time for chronotherapy in radiation oncology","volume":"11","author":"Berm\u00fadez-Guzm\u00e1n","year":"2021","journal-title":"Front Oncol"},{"key":"2026100803020316200_noag179-B79","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/cncr.24867","article-title":"Circadian variation in radiation-induced intestinal mucositis in patients with cervical carcinoma","volume":"116","author":"Shukla","year":"2010","journal-title":"Cancer"},{"key":"2026100803020316200_noag179-B80","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1080\/09553000902883802","article-title":"Oral mucositis in morning vs. evening irradiated patients: a randomised prospective study","volume":"85","author":"Goyal","year":"2009","journal-title":"Int J Radiat Biol"},{"key":"2026100803020316200_noag179-B81","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijrobp.2008.07.009","article-title":"Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the national cancer institute of Canada clinical trials group (HN3)","volume":"73","author":"Bjarnason","year":"2009","journal-title":"Int J Radiation Oncol Biol Phys"},{"key":"2026100803020316200_noag179-B82","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11060-019-03332-7","article-title":"Radiation chronotherapy-clinical impact of treatment time-of-day: a systematic review","volume":"145","author":"Shuboni-Mulligan","year":"2019","journal-title":"J Neurooncol"},{"key":"2026100803020316200_noag179-B83","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.clon.2019.02.010","article-title":"Is it time to change radiotherapy: the dawning of chronoradiotherapy?","volume":"31","author":"Harper","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2026100803020316200_noag179-B84","doi-asserted-by":"publisher","first-page":"vdab041","DOI":"10.1093\/noajnl\/vdab041","article-title":"Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study","volume":"3","author":"Damato","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2026100803020316200_noag179-B85","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.3390\/CURRONCOL30020147","article-title":"Temozolomide chronotherapy in glioma: a systematic review","volume":"30","author":"Jia","year":"2023","journal-title":"Curr Oncol"},{"key":"2026100803020316200_noag179-B86","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/00001813-199608000-00012","article-title":"Circadian variation in O6-methylguanine-DNA methyltransferase activity in mouse liver","volume":"7","author":"Martineau-Pivoteau","year":"1996","journal-title":"Anticancer Drugs"},{"key":"2026100803020316200_noag179-B87","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/nop\/npaf006","article-title":"Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: does time of administration matter?","volume":"12","author":"Geurts","year":"2025","journal-title":"Neurooncol Pract"},{"key":"2026100803020316200_noag179-B88","doi-asserted-by":"publisher","first-page":"32010","DOI":"10.1038\/s41598-025-17461-9","article-title":"Circadian rhythms in pediatric high-grade gliomas may contribute to treatment efficacy","volume":"15","author":"Nettnin","year":"2025","journal-title":"Sci Rep"},{"key":"2026100803020316200_noag179-B89","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.3747\/co.21.1769","article-title":"Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline","volume":"21","author":"Kostaras","year":"2014","journal-title":"Curr Oncol"},{"key":"2026100803020316200_noag179-B90","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00441-013-1762-z","article-title":"Glucocorticoids and endothelial cell barrier function","volume":"355","author":"Salvador","year":"2014","journal-title":"Cell Tissue Res"},{"key":"2026100803020316200_noag179-B91","doi-asserted-by":"publisher","first-page":"103625","DOI":"10.1016\/j.critrevonc.2022.103625","article-title":"Advantages and drawbacks of dexamethasone in glioblastoma multiforme","volume":"172","author":"Afshari","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026100803020316200_noag179-B92","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.3390\/cells10071783","article-title":"Sex-specific differences in glioblastoma","volume":"10","author":"Carrano","year":"2021","journal-title":"Cells"},{"key":"2026100803020316200_noag179-B93","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.molmed.2016.03.004","article-title":"Dosing-Time makes the poison: circadian regulation and pharmacotherapy","volume":"22","author":"Dallmann","year":"2016","journal-title":"Trends Mol Med"},{"key":"2026100803020316200_noag179-B94","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev.pharmtox.48.113006.094626","article-title":"Circadian timing in cancer treatments","volume":"50","author":"Levi","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026100803020316200_noag179-B95","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","article-title":"Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"2026100803020316200_noag179-B96","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.trecan.2025.06.011","article-title":"Time-of-day dependency of adoptive cell therapies","volume":"11","author":"Tellinga","year":"2025","journal-title":"Trends Cancer"},{"key":"2026100803020316200_noag179-B97","doi-asserted-by":"publisher","author":"Lyons","year":"2025","DOI":"10.1101\/2025.05.15.25327612"},{"key":"2026100803020316200_noag179-B98","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(97)03358-8","article-title":"Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer","volume":"350","author":"L\u00e9vi","year":"1997","journal-title":"Lancet"},{"key":"2026100803020316200_noag179-B99","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/CCO.0b013e3283571a8e","article-title":"Effect of cancer therapy on neural stem cells: implications for cognitive function","volume":"24","author":"Gibson","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"2026100803020316200_noag179-B100","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12070879","article-title":"Effects of hippocampal sparing radiotherapy on brain microstructure\u2014a diffusion tensor imaging analysis","volume":"12","author":"Dinkel","year":"2022","journal-title":"Brain Sci"},{"key":"2026100803020316200_noag179-B101","doi-asserted-by":"publisher","first-page":"12822","DOI":"10.1073\/pnas.1307301110","article-title":"Cranial irradiation compromises neuronal architecture in the hippocampus","volume":"110","author":"Parihar","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026100803020316200_noag179-B102","doi-asserted-by":"publisher","first-page":"e40844","DOI":"10.1371\/journal.pone.0040844","article-title":"Cranial irradiation alters dendritic spine density and morphology in the hippocampus","volume":"7","author":"Chakraborti","year":"2012","journal-title":"PLoS One"},{"key":"2026100803020316200_noag179-B103","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00429-014-0709-9","article-title":"Persistent changes in neuronal structure and synaptic plasticity caused by proton irradiation","volume":"220","author":"Parihar","year":"2015","journal-title":"Brain Struct Funct"},{"key":"2026100803020316200_noag179-B104","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/archneurol.2011.245","article-title":"Prefrontal cortex and executive function impairments in primary breast cancer","volume":"68","author":"Kesler","year":"2011","journal-title":"Arch Neurol"},{"key":"2026100803020316200_noag179-B105","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/hbm.21102","article-title":"Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer","volume":"32","author":"de Ruiter","year":"2011","journal-title":"Hum Brain Mapp"},{"key":"2026100803020316200_noag179-B106","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2011.37.0189","article-title":"Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy","volume":"30","author":"Koppelmans","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026100803020316200_noag179-B107","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cell.2018.10.049","article-title":"Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment","volume":"176","author":"Gibson","year":"2019","journal-title":"Cell"},{"key":"2026100803020316200_noag179-B108","doi-asserted-by":"publisher","first-page":"31545","DOI":"10.1038\/srep31545","article-title":"Elimination of microglia improves cognitive function following cranial irradiation","volume":"6","author":"Acharya","year":"2016","journal-title":"Sci Rep"},{"key":"2026100803020316200_noag179-B109","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.38865","article-title":"Rescue of cognitive function following fractionated brain irradiation in a novel preclinical glioma model","volume":"7","author":"Feng","year":"2018","journal-title":"Elife"},{"key":"2026100803020316200_noag179-B110","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12974-016-0671-y","article-title":"Colony-stimulating factor 1 receptor blockade prevents fractionated whole-brain irradiation-induced memory deficits","volume":"13","author":"Feng","year":"2016","journal-title":"J Neuroinflammation"},{"key":"2026100803020316200_noag179-B111","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s40478-019-0838-8","article-title":"Attenuation of neuroinflammation reverses Adriamycin-induced cognitive impairments","volume":"7","author":"Allen","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"2026100803020316200_noag179-B112","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.bbi.2014.11.009","article-title":"Microglia inflammatory responses are controlled by an intrinsic circadian clock","volume":"45","author":"Fonken","year":"2015","journal-title":"Brain Behav Immun"},{"key":"2026100803020316200_noag179-B113","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1038\/s41593-025-02067-1","article-title":"A glial circadian gene expression atlas reveals cell-type and disease-specific reprogramming in response to amyloid pathology or aging","volume":"28","author":"Sheehan","year":"2025","journal-title":"Nat Neurosci"},{"key":"2026100803020316200_noag179-B114","doi-asserted-by":"publisher","first-page":"102232","DOI":"10.1016\/j.arr.2024.102232","article-title":"Circadian regulation of microglia function: potential targets for treatment of Parkinson\u2019s Disease","volume":"95","author":"Kou","year":"2024","journal-title":"Ageing Res Rev"},{"key":"2026100803020316200_noag179-B115","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/glia.24261","article-title":"Circadian modulation of microglial physiological processes and immune responses","volume":"71","author":"Guzm\u00e1n-Ruiz","year":"2023","journal-title":"Glia"},{"key":"2026100803020316200_noag179-B116","doi-asserted-by":"publisher","author":"Mehl","year":"2025","DOI":"10.1101\/2025.11.11.687867"},{"key":"2026100803020316200_noag179-B117","doi-asserted-by":"publisher","DOI":"10.3390\/biology5030031","article-title":"Circadian regulation of synaptic plasticity","volume":"5","author":"Frank","year":"2016","journal-title":"Biology (Basel)"},{"key":"2026100803020316200_noag179-B118","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3389\/fnsys.2014.00164","article-title":"Circadian gating of neuronal functionality: a basis for iterative metaplasticity","volume":"8","author":"Iyer","year":"2014","journal-title":"Front Syst Neurosci"},{"key":"2026100803020316200_noag179-B119","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s12200-021-1090-y","article-title":"Relationship between circadian rhythm and brain cognitive functions","volume":"14","author":"Xu","year":"2021","journal-title":"Front Optoelectron"},{"key":"2026100803020316200_noag179-B120","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrn2881","article-title":"Circadian rhythms and memory formation","volume":"11","author":"Gerstner","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"2026100803020316200_noag179-B121","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/j.neuron.2025.07.012","article-title":"The neuroscience of brain cancers","volume":"113","author":"Monje","year":"2025","journal-title":"Neuron"},{"key":"2026100803020316200_noag179-B122","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.neuron.2019.04.011","article-title":"Gamma entrainment binds higher-order brain regions and offers neuroprotection","volume":"102","author":"Adaikkan","year":"2019","journal-title":"Neuron"},{"key":"2026100803020316200_noag179-B123","doi-asserted-by":"publisher","first-page":"eadf4601","DOI":"10.1126\/scitranslmed.adf4601","article-title":"Gamma entrainment using audiovisual stimuli alleviates chemobrain pathology and cognitive impairment induced by chemotherapy in mice","volume":"16","author":"Kim","year":"2024","journal-title":"Sci Transl Med"},{"key":"2026100803020316200_noag179-B124","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2478\/raon-2023-0044","article-title":"A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights","volume":"57","author":"Li","year":"2023","journal-title":"Radiol Oncol"},{"key":"2026100803020316200_noag179-B125","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer"},{"key":"2026100803020316200_noag179-B126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020174","article-title":"Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review","volume":"11","author":"Fabian","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026100803020316200_noag179-B127","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.critrevonc.2017.01.005","article-title":"Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients","volume":"111","author":"Mehta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026100803020316200_noag179-B128","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1227\/01.NEU.0000129551.64651.74","article-title":"PTK787\/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization","volume":"55","author":"Goldbrunner","year":"2004","journal-title":"Neurosurgery"},{"key":"2026100803020316200_noag179-B129","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1200\/jco.2004.22.90140.1512","article-title":"A phase I\/II trial of single-agent PTK 787\/ZK 222584 (PTK\/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM)","volume":"22","author":"Conrad","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026100803020316200_noag179-B130","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1200\/jco.2004.22.90140.1513","article-title":"A phase I\/II trial of PTK787\/ZK 222584 (PTK\/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM)","volume":"22","author":"Reardon","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026100803020316200_noag179-B131","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11060-010-0390-7","article-title":"Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide","volume":"103","author":"Gerstner","year":"2011","journal-title":"J Neurooncol"},{"key":"2026100803020316200_noag179-B132","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/nejmoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"2026100803020316200_noag179-B133","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"McLendon","year":"2008","journal-title":"Nature"},{"key":"2026100803020316200_noag179-B134","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1016\/j.wneu.2021.02.044","article-title":"Laser interstitial thermal therapy for glioblastoma: a single-center experience","volume":"149","author":"Traylor","year":"2021","journal-title":"World Neurosurg."},{"key":"2026100803020316200_noag179-B135","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/07487304251323318","article-title":"Biological fluid flows: signaling mediums for circadian timing","volume":"40","author":"Duyvesteyn","year":"2025","journal-title":"J Biol Rhythms"},{"key":"2026100803020316200_noag179-B136","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41698-023-00448-y","article-title":"First-in-human prospective trial of sonobiopsy in high-grade glioma patients using neuronavigation-guided focused ultrasound","volume":"7","author":"Yuan","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2026100803020316200_noag179-B137","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s44384-025-00014-9","article-title":"Sonobiopsy for sensitive and spatially targeted molecular diagnosis through integrating ultrasound with liquid biopsy","volume":"1","author":"Yuan","year":"2025","journal-title":"NPJ Acoustics"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag179\/71668077\/noag179.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag179\/71668077\/noag179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:02:08Z","timestamp":1791442928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article\/doi\/10.1093\/neuonc\/noag179\/8876079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":137,"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag179","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"article-number":"noag179"}}